Assess whether to resubmit, meet, or pause the program (c06891)

SITUATION In a company with a CMC site change mid-review, disproportionate reporting signal workbook is the evidence after a DSMB note on an imbalance that is not yet a signal. RWE evidence-strategy director has to pick To resubmit, meet, or Pause the program for this Pharma & Life Sciences Clinical and Evidence Strategy close using disproportionate reporting signal workbook.

DECISION RWE evidence-strategy director in a company with a CMC site change mid-review must choose To resubmit, meet, / Pause the program using disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. RWE evidence-strategy director can defend To resubmit, meet, from disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal in a Pharma & Life Sciences challenge. 2. RWE evidence-strategy director cannot defend To resubmit, meet, from disproportionate reporting signal workbook; Pause the program is what the extract actually supports after a DSMB note on an imbalance that is not yet a signal. 3. A DSMB note on an imbalance that is not yet a signal never reached the population in disproportionate reporting signal workbook — reopen intake, do not close to resubmit, meet, or. 4. Two facts in disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal conflict for RWE evidence-strategy director; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to resubmit, meet, or for RWE evidence-strategy director.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal). If disproportionate reporting signal workbook cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. If disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal cannot support To resubmit, meet, versus Pause the program on this Pharma & Life Sciences Clinical and Evidence Strategy close, RWE evidence-strategy director must state the unresolved clinical or safety evidence requirement explicitly.